Montelukast Teva (Montelukast Sodium)

Montelukast Sodium works by selectively blocking the cysteinyl leukotriene receptor type 1 (CysLT1). This inhibition prevents leukotrienes—potent inflammatory mediators—from binding to airway smooth muscle and other tissues, thereby reducing bronchoconstriction, mucus production, vascular leakage, and eosinophilic inflammation that underlie asthma and allergic rhinitis.

The appropriate dose of Montelukast Teva is set by the prescribing clinician based on the patient’s age, weight, severity of asthma or allergic rhinitis, and any concomitant therapies. The product is available only by prescription, and the prescriber will decide the exact strength and frequency that best matches the individual’s therapeutic needs.

Safety data for Montelukast during pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any possible risk to the fetus. Regarding lactation, small amounts may pass into breast milk; a healthcare professional should evaluate the risk‑benefit balance before continuing therapy while nursing.

To place an order, submit an enquiry on the Montelukast Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Montelukast is a leukotriene receptor antagonist, whereas inhaled corticosteroids (ICS) target a broader range of inflammatory pathways. Montelukast is often added as an adjunct to ICS for patients whose symptoms are not fully controlled, or used when inhaler technique is problematic. It offers oral administration, which can improve adherence, but it does not replace the anti‑inflammatory potency of high‑dose corticosteroids.

Montelukast Teva tablets should be stored at room temperature, below 25 °C. Keep them in the original blister or container, protect from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink where humidity is high, and keep the product out of reach of children.

Montelukast Teva is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should follow the specific dosing schedule provided by their healthcare professional and should not split, crush, or chew the tablet unless instructed otherwise.

Serious adverse events, although rare, include angioedema, eosinophilic granulomatosis with polyangiitis (formerly Churg‑Strauss syndrome), severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and neuropsychiatric effects like depression or suicidal thoughts. Any signs of swelling, rash, mood changes, or liver dysfunction should prompt immediate medical evaluation.

Montelukast Teva is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Patients with a history of severe allergic reactions, uncontrolled psychiatric illness, or those who have experienced serious leukotriene‑mediated disorders should avoid the medication unless a specialist determines it is safe.